Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Clinical Trial

Official title:

Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) Online Disease Monitoring Program (DMP)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04812106
• Other study ID #: UX007-CL402
• Status: Terminated
• Start date: July 25, 2022
• Est. completion date: October 27, 2022

Study information

• Verified date: November 2022
• Source: Ultragenyx Pharmaceutical Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.

Description:

The online LC-FAOD DMP is a non-interventional, prospective, observational disease-monitoring program conducted through a mobile/web-based application developed by the Sponsor. Participant data will be captured via the mobile/web-based application and entered into the database designed and maintained by the Sponsor and/or its designee. Additional objectives of the study are to benefit the LC-FAOD community by developing a comprehensive database for use by the LC-FAOD community to characterize patient experience, inform disease management, and enable further research, utilize the digital platform to notify patients, caregivers, and relevant patient advocacy groups of research studies and clinical trials and share aggregated and de-identified outputs to facilitate the exchange of information with patients and/or caregivers.

Participants can be on any treatment in order to participate. Medical management of the disease should continue as directed by the patient's physician(s). Specifically, no treatments, investigational agents, or experimental interventions will be provided as part of this online LC-FAOD DMP.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: October 27, 2022
• Est. primary completion date: October 27, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis of LC-FAOD including: carnitine palmitoyltransferase (CPT I or CPT II) deficiency, very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, trifunctional protein (TFP) deficiency, or carnitine-acylcarnitine translocase (CACT) deficiency.

• Willing and able to provide consent or, if a minor, provide assent and informed consent by their legally authorized representative.

• Access to the internet and an internet-enabled device.

• Reside in the geographical regions where the platform is supported and approved by applicable IRB/IEC and /or health authority.

• Not receiving triheptanoin through an Ultragenyx-sponsored interventional clinical trial or Ultragenyx Investigator Sponsored Trial (IST). NOTE: Individuals are eligible to participate in this online DMP if they previously participated in UX007 clinical trials, are currently participating in the in clinic UX007-CL401 (NCT04632953), are receiving triheptanoin through Expanded Access or Compassionate Use programs, or are receiving commercially available triheptanoin via prescription.

Related Conditions & MeSH terms

• Disease
• Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Intervention

Other:
• No Intervention
No Intervention

Locations

Country	Name	City	State
United States	Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Ultragenyx Pharmaceutical Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LC-FAOD Management: Nutrition and Dosing Utilized to Control LC-FAOD		10 years
Primary	LC-FAOD At-home Interventions: Types of Interventions Used	Interventions used to prevent or mitigate Major Clinical Events (MCEs)	10 years
Primary	LC-FAOD MCEs: Annualized Event Rate of all MCEs	MCEs include skeletal myopathy (rhabdomyolysis), hepatic (hypoglycemia, liver dysfunction), and cardiac disease (cardiomyopathy) events. An MCE is defined as any visit to the ED/acute care, hospitalization, emergency intervention (ie, any unscheduled administration of therapeutics in the clinic), or any similar event whether caused primarily by LC-FAOD or by an intercurrent illness complicated by LC-FAOD	10 years
Primary	LC-FAOD MCEs: Annualized Event Days in the Emergency Department (ED)/Hospital for all MCEs		10 years
Primary	LC-FAOD MCEs: Time to First MCE in all Newborn Patients (<=1 Year)		10 years
Primary	Disease Management as Assessed by Physical Activity		10 years
Primary	Patient Reported Outcomes: Infant and Toddler Quality of Life Questionnaire (ITQOL) Short Form		10 years
Primary	Patient Reported Outcomes: Short-Form 10 (SF-10) Health Survey for Children		10 years
Primary	Patient Reported Outcomes: Medical Outcomes Study 12-Item Short Form Version 2 (SF-12v2) for Adults		10 years
Primary	Participant Survey: Patient and Caregiver-Reported Outcomes		10 years
Primary	Participant Survey: Disease Symptoms		10 years
Primary	Participant Survey: Schooling and Work Status		10 years
Primary	Participant Survey: Absenteeism/Presenteeism		10 years
Primary	Participant Survey: EuroQol Group 5-dimension 5-level (EQ-5D-5L) Instrument		10 years
Primary	Healthcare Resource Utilization: LC-FAOD-related Medical Resource Use Over Time		10 years

External Links

•   Ultragenyx Patient Advocacy/LC-FAOD Disease Information